Archive: May 1, 2026

Business

Deepak Chem Tech Limited enters into agreement to build HyCO plant to secure long-term supply of key raw material for its Polycarbonate Project

May 1, 2026 by Adriana Carlson 0 Comments

VADODARA, India, May 1, 2026 /PRNewswire/ — Deepak Chem Tech Limited (“DCTL”), a wholly owned subsidiary of Deepak Nitrite Limited, enters into long-term agreement with Praxair (a Linde company) to build a HyCO plant to manufacture key raw materials for DCTL’s upcoming polycarbonate manufacturing facility at Padariya, Dahej, in the state of Gujarat.

Under the agreement, Praxair India will build, own and operate dedicated on-site facility to supply key feedstocks for polycarbonate production. The arrangement establishes a reliable, long-term supply of an essential input for the project.

The agreement brings together DCTL’s downstream materials platform with Praxair India’s expertise in industrial gas infrastructure and operations. The on-site model is expected to support consistent availability and operational efficiency, while enabling DCTL to maintain focus on its core expertise.

DCTL’s integrated Polycarbonate facility is intended to play a significant role in the domestic production of a high-performance material that serves several high-growth end-use segments in India, including automotive, electrical and electronics, construction, and consumer applications. The integrated supply arrangement with Praxair India has been structured to support product quality, scalability, and supply chain resilience as the project advances.

“This agreement marks an important step in advancing our polycarbonate project,” said Mr Meghav Mehta, ED & CEO, Deepak Chem Tech Limited. “A long-term arrangement of critical raw material supply through a dedicated on-site solution enhances execution visibility, supports efficient project delivery and creates value for our customers. We are pleased to partner with Praxair India, whose global expertise and wide capabilities align well with the requirements of this project.”

The on-site facility is expected to be commissioned in 2028, in line with Deepak Chem Tech Limited’s polycarbonate plant.

About Deepak Nitrite Limited:

Deepak Nitrite Limited (NSE: DEEPAKNTR) (BSE: 506401) is one of India’s fastest growing, integrated, advanced materials and chemical and petrochemical intermediates company. It has a diversified portfolio that caters to the dyes and pigments, agrochemical, pharmaceutical, plastics, textiles, paper and home, and personal care segments along with petro derivates intermediates – phenolics, acetone and IPA in India, and overseas. Its products are manufactured across six locations, which are all accredited by Responsible Care. Recognized globally as a “Responsible Manufacturer” and a “Supplier of Choice” by marquee customers.

Focusing on a Triple Bottomline principle of People, Planet, Profit, Deepak Nitrite Ltd. deploys globally benchmarked standards & systems, and is now accredited ‘Bronze Rating’ by EcoVadis in 2024, for sustainability initiatives.

 

Cision View original content:https://www.prnewswire.com/in/news-releases/deepak-chem-tech-limited-enters-into-agreement-to-build-hyco-plant-to-secure-long-term-supply-of-key-raw-material-for-its-polycarbonate-project-302759820.html

Deepak Chem Tech Limited enters into agreement to build HyCO plant to secure long-term supply of key raw material for its Polycarbonate Project

Business

Tendo Announces Agreement with InfuCare Rx to Expand Affordable, High-Quality Infusion Care Nationwide

May 1, 2026 by Neel Achary 0 Comments

Philadelphia, PA – May 1 – Tendo on Thursday announced a new agreement with InfuCare Rx®, a national infusion services provider, to expand access to high-quality, cost-effective infusion therapy through the Tendo Marketplace.

Infusion therapy is a major cost driver across autoimmune and inflammatory disorders, as well as neurology, hematology, and immuno-oncology. This relationship supports Tendo Marketplace’s broader mission to support ambulatory care and bring new specialty clinical categories to employers, health plans, and patients—particularly in areas with high cost and complex care needs.

“By working with InfuCare Rx, we are proud to expand access to innovative infusion care models that improve affordability while enhancing the patient experience,” said Ben Maisano, SVP Strategy at Tendo. “This relationship strengthens our national network and helps employers and plan sponsors better navigate some of the most expensive specialty therapies in the US.”

InfuCare Rx provides comprehensive infusion services through a growing national footprint, including:

  • 20+ infusion nursing offices and suites

  • Nationwide nursing and home infusion services

  • 300+ conditions treated

“We are excited to collaborate with Tendo to expand access to safe, high-quality infusion therapy in more convenient and cost-effective settings,” said Deven Patel, Founder and Chief Executive Officer at InfuCare Rx. “Together, we’re making it easier for patients to receive complex specialty treatments closer to home while helping payers and employers better manage specialty drug spending.”

InfuCare Rx enhances the infusion care experience by offering flexible care delivery options, including ambulatory clinics and in-home services. This approach supports cost-effective care while maintaining strong clinical oversight and improving convenience, reducing travel burden, and expanding access to specialty care nationwide.

“For patients undergoing ongoing infusion therapy, convenience and continuity of care make a meaningful difference,” said Mike Reese, VP Clinical Advocacy at Valenz. “Having access to trusted, home-based infusion options allows us to guide members toward high-quality care that fits their lives.”

The InfuCare Rx care delivery model includes standardized protocols and ongoing patient monitoring to support quality, safety, and outcomes across infusion therapies.

With the addition of InfuCare Rx, Tendo adds to its national infusion network for Tendo’s Marketplace, offering greater choice, value, and modern site-of-care options for patients and partners across the country.